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neurotoxicity typically occurs within the first month of therapy,
but it has been identified several months into the course of
treatment. Cyclosporine-induced neurotoxicity is not dose-related
and has been identified in patients with normal levels (1,6).
A constellation of CT and MRI findings has been reported by
several authors to be characteristic of cyclosporine-induced
neurotoxicity (5,6). CT typically demonstrates symmetrical
regions of nonenhancing low density within the white matter of
the posterior parietal and occipital lobes, with little mass effect.
MRI will show symmetrical areas characterized by signal hyper-
intensity on T2-weighted images, signal hypointensity on Tl-
weighted images, and by absence of enhancement on postcontrast
images. Occasionally, hemorrhage has been reported within such
lesions (5,6). While involvement of the parieto-occipital lobes is
most frequently encountered, reports suggest that white matter in
any part of the brain may be affected. These findings may persist
for several months despite discontinuation of cyclosporine treat
ment, and in the face of clinical improvement (6).
The presence of the characteristic findings on CT/MR imag
ing in combination with the most typical clinical manifestations
may yield a correct diagnosis; however, the actual incidence of
these typical findings remains unknown. Vogt et al. reported
that in 40% of patients postliver transplantation, CT was
interpreted as normal (4). A normal CT or a CT scan which
demonstrates a nonspecific white matter abnormality of inde
terminate age is not unusual. In such patients, whose neurolog
ical presentation may be atypical and whose cyclosporine levels
may fall within the normal range, the neurological differential
may be problematic.
The demonstration of perfusion abnormalities on SPECT
imaging may permit identification of those patients with cy
closporine-induced neurotoxicity and normal CT and MRI
studies. The more rapid resolution of the perfusion abnormali
ties, in comparison with the abnormalities on CT, more accu
rately paralleled the patient's clinical course. Our patient
presented with hypomagnesemia and hypocholesterolemia at
the onset of symptoms. Although these abnormalities as well as
hypertention and steroid administration have been identified as
exacerbating conditions, cause and effect have not been estab
lished (7,3,5,6), and the etiology of cyclosporine-induced neu
rotoxicity remains obscure. Demyelination has been suggested
as an explanation for the neuroimaging findings, however,
scattered pathological reports have failed to support this theory
(6-7). Truwit et al. have suggested that cyclosporine neurotox
icity may be the consequence of focal vasoconstriction produc
ing usually mild and reversible ischemia. They propose that
cyclosporine-induced neurotoxicity is mediated by the release
of endothelin, a neuropeptide which is a potent vasoconstrictor
(6). This claim is supported by the similarity found between the
neuroimaging findings in patients with eclampsia and acute
hypertensive encephalopathy (conditions in which endothelin is
already postulated to have a role) to those neuroimaging
findings described in patients with cyclosporine-induced neu
rotoxicity (6). Alternatively, Stein et al. suggest that cyclospo
rine may produce cerebral vasoconstriction by altering the balance
between prostacyclin and thromboxane A2 substances which have
been found to be vasoactive elsewhere in the body (3 ).
CONCLUSION
The demonstration of moderately decreased perfusion on
SPECT imaging corresponding to the regions of white matter
abnormalities identified on CT and MRI examinations in our
patient further supports the hypothesis that these abnormalities
reflect an ischemie insult rather than demyelination. Assuming
that the SPECT correlates better with the neurological symp
toms, it may eliminate prolonged discontinuation of much-needed
immunosuppression and the increased risk of organ rejection.
Further studies are needed to determine whether SPECT may be
used to identify cyclosporine-induced neurotoxicity in patients
whose other imaging studies are nondiagnostic.
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Reversible Extraskeletal Uptake of Bone Scanning
in Primary Hyperparathyroidism
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Metastatic calcification within soft tissue, such as the lung and sto
mach, is associated with hyperparathyroidism, chronic renal failure,
hemodialysis, metastatic neoplasm and hypervitaminosis D. Bone
scanning agents variably accumulate within these extraskeletal met
astatic calcifications. We report a patient with primary hyperparathy-
roidism whose bone scan revealed abnormal uptake in the liver, lung,
stomach and parathyroid gland followed by complete resolution of
extraskeletal uptake less than 1 wk after parathyroidectomy.
Key Words: metastaticcalcification;hyperparathyroidism;bone scin-
tigraphy
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the introduction of the y9mTc-phosphate compounds, un
usual extraosseous accumulations have been reported, in which
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FIGURE 1. Anterior bone scan. Intense accumulation of radioactivity is seen
throughout the lung, liver, stomach and left lobe of the thyroid gland.
chemiadsorption into the hydroxyapatite crystals is the proposed
mechanism of uptake (1-4). The resolution of metastatic calcium
deposits of hypercalcemia is somewhat controversial. We recently
observed complete reversal of uptake in extraosseous sites (i.e.,
lung, liver, stomach) in a patient with primary hyperparathyroid-
ism 1 wk after partial parathyroidectomy. Following the resolution
of extraskeletal uptake on repeated subsequent postoperative bone
scans, an interesting feature occurred: the appearance of intense
uptake within the calvarium and mandible which was not demon
strated on the initial bone scan.
CASE REPORT
A 65-yr-old woman was admitted for evaluation of hypercalce
mia. Her symptoms consisted of poor oral intake, nausea, fatigue,
weight loss (4 kg), indigestion, constipation and polydipsia for 2
wk. On physical examination, a palpable nodule was noted in the
neck. The laboratory data at that time showed elevated serum
calcium (17.0 mg/dl), serum phosphate (6.6 mg/dl), blood urea
nitrogen (59.2 mg/dl), serum creatinine (2.5 mg/dl) and serum
alkaline phosphatase (127 mg/dl). Liver function tests were nor
mal. Amino-terminal radioimmunoassay disclosed a serum
parathormone concentration of 145.16 pg/ml (normal 10-65 pg/
ml). Thyroid test showed a low serum level of the thyroid
hormones; T3 32.75 ng/dl (80-220 ng/dl), and FT4 0.76 ng/dl
(0.73-1.95 ng/dl). A plain radiograph of the hands showed sub-
periosteal rÃ©sorptionof the phalanges. A chest radiograph did not
reveal any pathologic calcification in bilateral lungs. A CT scan of
the neck showed a well-defined 4 X 3 X 2-cm mass on the left
lower neck, posterior to the left thyroid gland and medial to the
jugular vein. On the basis of the laboratory and CT findings,
parathyroid adenoma was diagnosed. A bone scan performed 4 hr
after intravenous injection of 20 mCi 99mTc-MDP revealed in
creased uptake diffusely throughout the lung, liver, stomach and
locally at the left thyroid region (Fig. 1).
Seven days later, a 5 X 2-cm benign adenoma was surgically
removed. It was located posterior to the left lobe of the thyroid,
originating from the left superior parathyroid and extended to the
lower pole of the thyroid. After surgery, serum calcium and
phosphorus levels decreased to almost normal ranges (serum
FIGURE 2. Bone scan performed 1
wk after removal of a parathyroid
adenoma shows complete resolu
tion of extraskeletal uptake and in
tense activity in the calvarium, man
dible and long bones.
calcium, 8.6 mg/dl and phosphate, 3.0 mg/dl). A repeat bone scan
1 wk after the operation exhibited complete disappearance of
extraskeletal uptake. Intense uptake at the calvarium, mandible and
long bones with faint renal activity was visualized (Fig. 2).
DISCUSSION
Pathologic calcification is classified into two types: dystro-
phic and metastatic (5). Dystrophie calcification occurs after
tissue injury in the presence of normal plasma calcium and
phosphate concentrations. In contrast, metastatic calcification is
calcium deposits within extraskeletal tissues due to abnormal
calcium and phosphate metabolism. The etiology of the meta
static calcification includes primary or secondary osteolytic
bone tumors, hyperparathyroidism, hypervitaminosis D and
chronic renal failure.
In primary hyperparathyroidism, visceral uptake of 99mTc-
labeled phosphate compounds and unusual extraosseous accu
mulations have been reported. It is generally accepted that the
metastatic calcification is predominantly related to an increased
Ca X PO4 product. A rate above 60 seems necessary for the
presence of this type of calcification (6). In our patient, this
product was 112. The affected tissues are either solely those of
the lungs (7,8) or the lung tissues in association with gastric (9),
renal (10), myocardial (9, JO) and thyroidal (9) uptake. There
have been few reports on metastatic calcification to the liver.
Our patient showed exceptional metastatic uptake to the liver, in
addition to stomach and lung. Moreover, 1 wk after the removal of
the tumor resulted in resolution of the extraskeletal uptake and the
Ca X PO4 product was decreased to 25.8. Fundamentally, lower-
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ing Ã‡aX PO4 products by manipulating Ca and PO4 levels can
lead to drastic resolution of these calcifications (11). Alfrey et al.
(12) have already demonstrated radiologically the disappearance
of gross tumoral calcifications of chronic uremia after transplan
tation, either by phosphate supplementation or parathyroidectomy.
We could not correlate the metastatic calcium deposits by
bone scan with the anatomic presence of calcification. Radio
logical diagnosis of diffuse metastatic calcification has proven
to be difficult, as the particles are extremely small (microscopic
in most cases) (13). Lack of MDP uptake by metastatic calcium
deposits does not mean the disappearance of the anatomic
presence of calcification but represents the metastatic activity of
the pathologic calcification.
Among the important bone scintigraphic findings in hyper-
parathyroidism, uniformly increased bone-to-soft tissue ratios
generally associated with faint or absent renal visualization
(14-16) are a well known classical findings. The mechanism
for the super scan is due to low excretion of injected 99mTc-
MDP (10% in 4 hr versus 60% in normal subjects) and a
fivefold increase in the total bone-to-soft tissue uptake ratio
(17). Faint or absent kidney images are due to low soft-tissue
activity common to any metabolic bone disease with high bone
uptake of 99mTc-diphosphonate (77).
In our patient, the skeletal and renal uptake appeared normal
in the first bone scan, whereas the second one, obtained 1 wk
after surgery, showed generalized increased activity symmetri
cally, particularly in the calvarium, the mandible and the
diaphysis of long bone (18). Relatively higher 99mTc-MDP
uptake in extraskeletal sites may have prevented the appearance
of this characteristic feature of hyperparathyroidism in the first
bone scan. After surgery, extraskeletal uptake of the radiophar-
maceutical decreased, thus allowing the appearance of hyper
parathyroidism features on the bone scan.
CONCLUSION
Hepatic, pulmonary and gastric uptake of 99mTc-MDP could
be reversed in primary hyperparathyroidism as the cause of
hypercalcemia is resolved. Therefore, the resolution of the
extraskeletal metastatic calcification can be correctly assessed
with repeat follow-up bone scintigraphy.
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Localization of Technetium-99m-Sestamibi
in Diffuse Myelodysplastic Processes
Robert E. Reiman and Julie K. Fetters
Departments of Radiology and Medicine, Duke University Medical Center, Durham, North Carolina
We present two patients with skeletal localization of ""Tc-sesta-
mibi in patients with ringed sideroblastic anemia and polycythemia
vera who were undergoing routine myocardial perfusion studies.
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lechnetium-99m-sestamibi (hexakis-2-methoxyisobutylisoni-
trile 99mTc(I)) was originally developed as a myocardial perfu
sion imaging agent and has been widely used in the diagnosis of
coronary artery disease since its introduction. It has, however,
Received Jan. 24, 1995; revision accepted Jun. 17, 1995.
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been shown to preferentially concentrate in a variety of solid
tumors. We report the incidental finding of skeletal localization
of 99mTc-sestamibi in two patients with diffuse myelodysplastic
processes.
CASE REPORT
Patient One
A 73-yr-old man was referred for evaluation of a 3-wk history of
dyspnea on exertion and palpitations in view of a family history of
coronary artery disease. He underwent a myocardial perfusion
study utilizing a one-day imaging protocol and received 296 MBq
(8.0 mCi) "Tc-sestamibi at rest, followed 60 min later by planar
imaging in the anterior, 45Â°LAO and left lateral projections.
Imaging was repeated following treadmill exercise using 888 MBq
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